Avoro Capital Advisors LLC Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Avoro Capital Advisors LLC increased its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 0.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,628,822 shares of the company’s stock after purchasing an additional 6,600 shares during the quarter. Krystal Biotech makes up 5.8% of Avoro Capital Advisors LLC’s portfolio, making the stock its 5th largest holding. Avoro Capital Advisors LLC owned approximately 0.09% of Krystal Biotech worth $411,831,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in KRYS. Wilmington Savings Fund Society FSB acquired a new stake in shares of Krystal Biotech in the 3rd quarter valued at $40,000. Covestor Ltd grew its stake in Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after buying an additional 642 shares during the last quarter. Avanza Fonder AB acquired a new stake in shares of Krystal Biotech during the fourth quarter worth approximately $119,000. KBC Group NV boosted its holdings in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock worth $147,000 after acquiring an additional 297 shares in the last quarter. Finally, Blue Trust Inc. grew its position in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after acquiring an additional 433 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Performance

Shares of KRYS opened at $168.57 on Monday. The stock has a 50 day simple moving average of $175.10 and a 200 day simple moving average of $171.83. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34. The firm has a market capitalization of $4.87 billion, a PE ratio of 56.38 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. During the same quarter in the prior year, the company earned $0.30 earnings per share. The business’s quarterly revenue was up 116.4% compared to the same quarter last year. Equities research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on KRYS shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Citigroup boosted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Friday, February 28th. Finally, Chardan Capital boosted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $220.00.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 13.70% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).